182 related articles for article (PubMed ID: 19689789)
41. Role of endocrine therapy in the neoadjuvant surgical setting.
Dixon JM
Ann Surg Oncol; 2004 Jan; 11(1 Suppl):18S-23S. PubMed ID: 15015705
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Dahhan T; Balkenende E; van Wely M; Linn S; Goddijn M
Cochrane Database Syst Rev; 2013 Nov; (11):CD010240. PubMed ID: 24213953
[TBL] [Abstract][Full Text] [Related]
43. Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.
Louis DM; Nair LM; Vijaykumar DK; Vallonthaiel AG; Yesodharan J; Bhaskaran R; Narmadha MP
Breast Dis; 2023; 42(1):27-36. PubMed ID: 36872762
[TBL] [Abstract][Full Text] [Related]
44. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
45. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Smith IE
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
[TBL] [Abstract][Full Text] [Related]
46. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
47. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
48. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
[TBL] [Abstract][Full Text] [Related]
49. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
[TBL] [Abstract][Full Text] [Related]
50. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
51. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
52. DCIS and aromatase inhibitors.
Dixon JM; Faratian D; White S; Renshaw L; Murray J; Young O; Macaskill EJ; Williams L; Thomas J; Evans DB
J Steroid Biochem Mol Biol; 2007; 106(1-5):173-9. PubMed ID: 17604618
[TBL] [Abstract][Full Text] [Related]
53. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
[TBL] [Abstract][Full Text] [Related]
54. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
Miller WR; Dixon JM; Macfarlane L; Cameron D; Anderson TJ
Eur J Cancer; 2003 Mar; 39(4):462-8. PubMed ID: 12751376
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Ellis MJ; Rosen E; Dressman H; Marks J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):301-7. PubMed ID: 14623525
[TBL] [Abstract][Full Text] [Related]
56. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
57. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Mouridsen H; Gershanovich M; Sun Y; Pérez-Carrión R; Boni C; Monnier A; Apffelstaedt J; Smith R; Sleeboom HP; Jänicke F; Pluzanska A; Dank M; Becquart D; Bapsy PP; Salminen E; Snyder R; Lassus M; Verbeek JA; Staffler B; Chaudri-Ross HA; Dugan M
J Clin Oncol; 2001 May; 19(10):2596-606. PubMed ID: 11352951
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
60. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
